Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.
Vanita R ArodaUmut ErhanPeter JelnesJuris J MeierMorten Tind AbildlundRichard E PratleyTina VilsbøllMansoor HusainPublished in: Diabetes, obesity & metabolism (2023)
The most common AEs with semaglutide were gastrointestinal disorders, which decreased with continued therapy. These comprehensive safety/tolerability data may better inform patient selection and guidance in care.